Laboratory of Genetics and Molecular Biology, Department of Biomedicine, Academic Unit of Health Sciences, Federal University of Jataí-UFJ, BR 364, km 195, nº 3800, CEP 75801-615, Jataí, GO, Brazil.
Biomed Pharmacother. 2021 Apr;136:111272. doi: 10.1016/j.biopha.2021.111272. Epub 2021 Jan 12.
Coronavirus disease 19 (COVID-19) continues to challenge most scientists in the search of an effective way to either prevent infection or to avoid spreading of the disease. As result of global efforts some advances have been reached and we are more prepared today than we were at the beginning of the pandemic, however not enough to stop the transmission, and many questions remain unanswered. The possibility of reinfection of recovered individuals, the duration of the immunity, the impact of SARS-CoV-2 mutations in the spreading of the disease as well as the degree of protection that a potential vaccine could have are some of the issues under debate. A number of vaccines are under development using different platforms and clinical trials are ongoing in different countries, but even if they are licensed it will need time until reach a definite conclusion about their real safety and efficacy. Herein we discuss the different strategies used in the development of COVID-19 vaccines, the questions underlying the type of immune response they may elicit, the consequences that new mutations may have in the generation of sub-strains of SARS-CoV-2 and their impact and challenges for the efficacy of potential vaccines in a scenario postpandemic.
新型冠状病毒病(COVID-19)继续挑战着大多数科学家,他们正在寻找一种有效的方法来预防感染或避免疾病传播。由于全球的努力,已经取得了一些进展,与大流行开始时相比,我们今天的准备更加充分,但还不足以阻止传播,并且仍有许多问题尚未得到解答。康复者再次感染的可能性、免疫的持续时间、SARS-CoV-2 突变对疾病传播的影响以及潜在疫苗的保护程度等问题仍存在争议。目前正在使用不同平台开发多种疫苗,不同国家正在进行临床试验,但即使获得许可,也需要时间才能得出关于其真正安全性和有效性的明确结论。在此,我们讨论了 COVID-19 疫苗开发中使用的不同策略、它们可能引发的免疫反应类型背后的问题、新突变可能对 SARS-CoV-2 亚株产生的影响及其对潜在疫苗在大流行后的有效性的影响和挑战。